Vaxcyte, Inc. (NASDAQ:PCVX) Position Raised by New York Life Investment Management LLC

New York Life Investment Management LLC increased its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 4.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,469 shares of the company’s stock after purchasing an additional 494 shares during the period. New York Life Investment Management LLC’s holdings in Vaxcyte were worth $1,021,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Whipplewood Advisors LLC bought a new stake in Vaxcyte during the fourth quarter worth approximately $28,000. Meeder Asset Management Inc. raised its holdings in Vaxcyte by 1,007.9% during the third quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock worth $80,000 after purchasing an additional 635 shares in the last quarter. Blue Trust Inc. grew its position in Vaxcyte by 100.0% in the fourth quarter. Blue Trust Inc. now owns 742 shares of the company’s stock worth $61,000 after buying an additional 371 shares during the last quarter. Nomura Asset Management Co. Ltd. acquired a new position in Vaxcyte in the third quarter worth approximately $92,000. Finally, AlphaCentric Advisors LLC acquired a new position in Vaxcyte in the fourth quarter worth approximately $161,000. Institutional investors own 96.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on PCVX. Needham & Company LLC restated a “buy” rating and issued a $140.00 price target on shares of Vaxcyte in a research report on Wednesday, February 26th. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a research report on Wednesday, November 6th. The Goldman Sachs Group began coverage on shares of Vaxcyte in a research report on Friday, December 20th. They issued a “buy” rating and a $135.00 price target on the stock. Finally, Guggenheim restated a “buy” rating and issued a $160.00 price target on shares of Vaxcyte in a research report on Wednesday, February 26th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $147.50.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, Director Teri Loxam sold 6,250 shares of Vaxcyte stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total transaction of $531,937.50. Following the completion of the sale, the director now owns 7,175 shares of the company’s stock, valued at $610,664.25. This trade represents a 46.55 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Mikhail Eydelman sold 5,000 shares of Vaxcyte stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $91.49, for a total transaction of $457,450.00. Following the sale, the senior vice president now directly owns 28,697 shares of the company’s stock, valued at $2,625,488.53. This trade represents a 14.84 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 61,616 shares of company stock valued at $5,225,971 in the last quarter. Company insiders own 3.10% of the company’s stock.

Vaxcyte Stock Performance

NASDAQ PCVX opened at $72.10 on Tuesday. Vaxcyte, Inc. has a twelve month low of $58.10 and a twelve month high of $121.06. The stock has a market cap of $9.28 billion, a price-to-earnings ratio of -15.67 and a beta of 0.98. The firm’s 50 day moving average price is $84.30 and its two-hundred day moving average price is $94.91.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, topping the consensus estimate of ($1.16) by $0.14. On average, research analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.